PubMed:33118200 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":811,"end":816},"obj":"Body_part"},{"id":"T2","span":{"begin":876,"end":886},"obj":"Body_part"},{"id":"T3","span":{"begin":922,"end":927},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma9576"}],"text":"Clinical features of patients undergoing hemodialysis with COVID-19.\nHemodialysis patients are susceptible to coronavirus disease 2019 (COVID-19). The aim of this study was to describe the epidemiological, clinical characteristics, and mortality-related risk factors for those who undergoing hemodialysis with COVID-19. We conducted a retrospective study. A total of 49 hemodialysis patients with COVID-19 (Group 1) and 74 uninfected patients (Group 2) were included. For patients in Group 1, we found the median age was 62 years (36-89 years), 59.3% were male, and the median dialysis vintage was 26 months. Twenty-eight patients (57%) had three or more comorbidities and two patients (4%) died. The most common symptoms were fever (32.7%) and dry cough (46.9%), while nine patients (18.4%) were asymptomatic. Blood routine tests indicated lymphocytopenia, the proportion of lymphocyte subsets was generally reduced, and chest CT scans showed ground-glass opacity (45.8%) and patchy shadowing (35.4%). However, these findings were not specific to hemodialysis patients with COVID-19, and similar manifestations could be found in patients without SARS-CoV-2 infection. In conclusion, for hemodialysis patients with COVID-19, lymphocytopenia and ground-glass opacities or patchy opacities were common but not specific to them, early active treatment and interventions against nosocomial infection can significantly reduce the mortality and the risk of SARS-CoV-2 infection."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":811,"end":816},"obj":"Body_part"},{"id":"T2","span":{"begin":922,"end":927},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"}],"text":"Clinical features of patients undergoing hemodialysis with COVID-19.\nHemodialysis patients are susceptible to coronavirus disease 2019 (COVID-19). The aim of this study was to describe the epidemiological, clinical characteristics, and mortality-related risk factors for those who undergoing hemodialysis with COVID-19. We conducted a retrospective study. A total of 49 hemodialysis patients with COVID-19 (Group 1) and 74 uninfected patients (Group 2) were included. For patients in Group 1, we found the median age was 62 years (36-89 years), 59.3% were male, and the median dialysis vintage was 26 months. Twenty-eight patients (57%) had three or more comorbidities and two patients (4%) died. The most common symptoms were fever (32.7%) and dry cough (46.9%), while nine patients (18.4%) were asymptomatic. Blood routine tests indicated lymphocytopenia, the proportion of lymphocyte subsets was generally reduced, and chest CT scans showed ground-glass opacity (45.8%) and patchy shadowing (35.4%). However, these findings were not specific to hemodialysis patients with COVID-19, and similar manifestations could be found in patients without SARS-CoV-2 infection. In conclusion, for hemodialysis patients with COVID-19, lymphocytopenia and ground-glass opacities or patchy opacities were common but not specific to them, early active treatment and interventions against nosocomial infection can significantly reduce the mortality and the risk of SARS-CoV-2 infection."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":59,"end":67},"obj":"Disease"},{"id":"T2","span":{"begin":110,"end":134},"obj":"Disease"},{"id":"T3","span":{"begin":136,"end":144},"obj":"Disease"},{"id":"T4","span":{"begin":310,"end":318},"obj":"Disease"},{"id":"T5","span":{"begin":397,"end":405},"obj":"Disease"},{"id":"T6","span":{"begin":841,"end":856},"obj":"Disease"},{"id":"T7","span":{"begin":1075,"end":1083},"obj":"Disease"},{"id":"T8","span":{"begin":1147,"end":1155},"obj":"Disease"},{"id":"T9","span":{"begin":1158,"end":1167},"obj":"Disease"},{"id":"T10","span":{"begin":1215,"end":1223},"obj":"Disease"},{"id":"T11","span":{"begin":1225,"end":1240},"obj":"Disease"},{"id":"T12","span":{"begin":1375,"end":1395},"obj":"Disease"},{"id":"T13","span":{"begin":1386,"end":1395},"obj":"Disease"},{"id":"T14","span":{"begin":1451,"end":1459},"obj":"Disease"},{"id":"T15","span":{"begin":1462,"end":1471},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0003783"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0003783"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0043544"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Clinical features of patients undergoing hemodialysis with COVID-19.\nHemodialysis patients are susceptible to coronavirus disease 2019 (COVID-19). The aim of this study was to describe the epidemiological, clinical characteristics, and mortality-related risk factors for those who undergoing hemodialysis with COVID-19. We conducted a retrospective study. A total of 49 hemodialysis patients with COVID-19 (Group 1) and 74 uninfected patients (Group 2) were included. For patients in Group 1, we found the median age was 62 years (36-89 years), 59.3% were male, and the median dialysis vintage was 26 months. Twenty-eight patients (57%) had three or more comorbidities and two patients (4%) died. The most common symptoms were fever (32.7%) and dry cough (46.9%), while nine patients (18.4%) were asymptomatic. Blood routine tests indicated lymphocytopenia, the proportion of lymphocyte subsets was generally reduced, and chest CT scans showed ground-glass opacity (45.8%) and patchy shadowing (35.4%). However, these findings were not specific to hemodialysis patients with COVID-19, and similar manifestations could be found in patients without SARS-CoV-2 infection. In conclusion, for hemodialysis patients with COVID-19, lymphocytopenia and ground-glass opacities or patchy opacities were common but not specific to them, early active treatment and interventions against nosocomial infection can significantly reduce the mortality and the risk of SARS-CoV-2 infection."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":151,"end":154},"obj":"http://purl.obolibrary.org/obo/PR_000001343"},{"id":"T2","span":{"begin":333,"end":334},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T3","span":{"begin":356,"end":357},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T4","span":{"begin":531,"end":533},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T5","span":{"begin":556,"end":560},"obj":"http://purl.obolibrary.org/obo/UBERON_0003101"},{"id":"T6","span":{"begin":556,"end":560},"obj":"http://www.ebi.ac.uk/efo/EFO_0000970"},{"id":"T7","span":{"begin":811,"end":816},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T8","span":{"begin":811,"end":816},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T9","span":{"begin":825,"end":830},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T10","span":{"begin":922,"end":927},"obj":"http://www.ebi.ac.uk/efo/EFO_0000965"},{"id":"T11","span":{"begin":1332,"end":1338},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"Clinical features of patients undergoing hemodialysis with COVID-19.\nHemodialysis patients are susceptible to coronavirus disease 2019 (COVID-19). The aim of this study was to describe the epidemiological, clinical characteristics, and mortality-related risk factors for those who undergoing hemodialysis with COVID-19. We conducted a retrospective study. A total of 49 hemodialysis patients with COVID-19 (Group 1) and 74 uninfected patients (Group 2) were included. For patients in Group 1, we found the median age was 62 years (36-89 years), 59.3% were male, and the median dialysis vintage was 26 months. Twenty-eight patients (57%) had three or more comorbidities and two patients (4%) died. The most common symptoms were fever (32.7%) and dry cough (46.9%), while nine patients (18.4%) were asymptomatic. Blood routine tests indicated lymphocytopenia, the proportion of lymphocyte subsets was generally reduced, and chest CT scans showed ground-glass opacity (45.8%) and patchy shadowing (35.4%). However, these findings were not specific to hemodialysis patients with COVID-19, and similar manifestations could be found in patients without SARS-CoV-2 infection. In conclusion, for hemodialysis patients with COVID-19, lymphocytopenia and ground-glass opacities or patchy opacities were common but not specific to them, early active treatment and interventions against nosocomial infection can significantly reduce the mortality and the risk of SARS-CoV-2 infection."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":556,"end":560},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_30780"}],"text":"Clinical features of patients undergoing hemodialysis with COVID-19.\nHemodialysis patients are susceptible to coronavirus disease 2019 (COVID-19). The aim of this study was to describe the epidemiological, clinical characteristics, and mortality-related risk factors for those who undergoing hemodialysis with COVID-19. We conducted a retrospective study. A total of 49 hemodialysis patients with COVID-19 (Group 1) and 74 uninfected patients (Group 2) were included. For patients in Group 1, we found the median age was 62 years (36-89 years), 59.3% were male, and the median dialysis vintage was 26 months. Twenty-eight patients (57%) had three or more comorbidities and two patients (4%) died. The most common symptoms were fever (32.7%) and dry cough (46.9%), while nine patients (18.4%) were asymptomatic. Blood routine tests indicated lymphocytopenia, the proportion of lymphocyte subsets was generally reduced, and chest CT scans showed ground-glass opacity (45.8%) and patchy shadowing (35.4%). However, these findings were not specific to hemodialysis patients with COVID-19, and similar manifestations could be found in patients without SARS-CoV-2 infection. In conclusion, for hemodialysis patients with COVID-19, lymphocytopenia and ground-glass opacities or patchy opacities were common but not specific to them, early active treatment and interventions against nosocomial infection can significantly reduce the mortality and the risk of SARS-CoV-2 infection."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2","span":{"begin":21,"end":29},"obj":"Species"},{"id":"3","span":{"begin":59,"end":67},"obj":"Disease"},{"id":"30","span":{"begin":82,"end":90},"obj":"Species"},{"id":"31","span":{"begin":110,"end":134},"obj":"Disease"},{"id":"32","span":{"begin":136,"end":144},"obj":"Disease"},{"id":"33","span":{"begin":236,"end":245},"obj":"Disease"},{"id":"34","span":{"begin":310,"end":318},"obj":"Disease"},{"id":"35","span":{"begin":383,"end":391},"obj":"Species"},{"id":"36","span":{"begin":397,"end":405},"obj":"Disease"},{"id":"37","span":{"begin":434,"end":442},"obj":"Species"},{"id":"38","span":{"begin":472,"end":480},"obj":"Species"},{"id":"39","span":{"begin":622,"end":630},"obj":"Species"},{"id":"40","span":{"begin":677,"end":685},"obj":"Species"},{"id":"41","span":{"begin":691,"end":695},"obj":"Disease"},{"id":"42","span":{"begin":727,"end":732},"obj":"Disease"},{"id":"43","span":{"begin":745,"end":754},"obj":"Disease"},{"id":"44","span":{"begin":775,"end":783},"obj":"Species"},{"id":"45","span":{"begin":841,"end":856},"obj":"Disease"},{"id":"46","span":{"begin":1061,"end":1069},"obj":"Species"},{"id":"47","span":{"begin":1075,"end":1083},"obj":"Disease"},{"id":"48","span":{"begin":1130,"end":1138},"obj":"Species"},{"id":"49","span":{"begin":1147,"end":1167},"obj":"Disease"},{"id":"50","span":{"begin":1201,"end":1209},"obj":"Species"},{"id":"51","span":{"begin":1215,"end":1223},"obj":"Disease"},{"id":"52","span":{"begin":1225,"end":1240},"obj":"Disease"},{"id":"53","span":{"begin":1375,"end":1395},"obj":"Disease"},{"id":"54","span":{"begin":1425,"end":1434},"obj":"Disease"},{"id":"55","span":{"begin":1451,"end":1471},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"tao:has_database_id","subj":"2","obj":"Tax:9606"},{"id":"A3","pred":"tao:has_database_id","subj":"3","obj":"MESH:C000657245"},{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"Tax:9606"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"MESH:C000657245"},{"id":"A32","pred":"tao:has_database_id","subj":"32","obj":"MESH:C000657245"},{"id":"A33","pred":"tao:has_database_id","subj":"33","obj":"MESH:D003643"},{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"MESH:C000657245"},{"id":"A35","pred":"tao:has_database_id","subj":"35","obj":"Tax:9606"},{"id":"A36","pred":"tao:has_database_id","subj":"36","obj":"MESH:C000657245"},{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"Tax:9606"},{"id":"A38","pred":"tao:has_database_id","subj":"38","obj":"Tax:9606"},{"id":"A39","pred":"tao:has_database_id","subj":"39","obj":"Tax:9606"},{"id":"A40","pred":"tao:has_database_id","subj":"40","obj":"Tax:9606"},{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"MESH:D003643"},{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"MESH:D005334"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"MESH:D003371"},{"id":"A44","pred":"tao:has_database_id","subj":"44","obj":"Tax:9606"},{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"MESH:D008231"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"Tax:9606"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"MESH:C000657245"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"Tax:9606"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"MESH:C000657245"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"Tax:9606"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"MESH:C000657245"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"MESH:D008231"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"MESH:D003428"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"MESH:D003643"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Clinical features of patients undergoing hemodialysis with COVID-19.\nHemodialysis patients are susceptible to coronavirus disease 2019 (COVID-19). The aim of this study was to describe the epidemiological, clinical characteristics, and mortality-related risk factors for those who undergoing hemodialysis with COVID-19. We conducted a retrospective study. A total of 49 hemodialysis patients with COVID-19 (Group 1) and 74 uninfected patients (Group 2) were included. For patients in Group 1, we found the median age was 62 years (36-89 years), 59.3% were male, and the median dialysis vintage was 26 months. Twenty-eight patients (57%) had three or more comorbidities and two patients (4%) died. The most common symptoms were fever (32.7%) and dry cough (46.9%), while nine patients (18.4%) were asymptomatic. Blood routine tests indicated lymphocytopenia, the proportion of lymphocyte subsets was generally reduced, and chest CT scans showed ground-glass opacity (45.8%) and patchy shadowing (35.4%). However, these findings were not specific to hemodialysis patients with COVID-19, and similar manifestations could be found in patients without SARS-CoV-2 infection. In conclusion, for hemodialysis patients with COVID-19, lymphocytopenia and ground-glass opacities or patchy opacities were common but not specific to them, early active treatment and interventions against nosocomial infection can significantly reduce the mortality and the risk of SARS-CoV-2 infection."}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":68},"obj":"Sentence"},{"id":"T2","span":{"begin":69,"end":146},"obj":"Sentence"},{"id":"T3","span":{"begin":147,"end":319},"obj":"Sentence"},{"id":"T4","span":{"begin":320,"end":355},"obj":"Sentence"},{"id":"T5","span":{"begin":356,"end":467},"obj":"Sentence"},{"id":"T6","span":{"begin":468,"end":608},"obj":"Sentence"},{"id":"T7","span":{"begin":609,"end":696},"obj":"Sentence"},{"id":"T8","span":{"begin":697,"end":810},"obj":"Sentence"},{"id":"T9","span":{"begin":811,"end":1002},"obj":"Sentence"},{"id":"T10","span":{"begin":1003,"end":1168},"obj":"Sentence"},{"id":"T11","span":{"begin":1169,"end":1472},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Clinical features of patients undergoing hemodialysis with COVID-19.\nHemodialysis patients are susceptible to coronavirus disease 2019 (COVID-19). The aim of this study was to describe the epidemiological, clinical characteristics, and mortality-related risk factors for those who undergoing hemodialysis with COVID-19. We conducted a retrospective study. A total of 49 hemodialysis patients with COVID-19 (Group 1) and 74 uninfected patients (Group 2) were included. For patients in Group 1, we found the median age was 62 years (36-89 years), 59.3% were male, and the median dialysis vintage was 26 months. Twenty-eight patients (57%) had three or more comorbidities and two patients (4%) died. The most common symptoms were fever (32.7%) and dry cough (46.9%), while nine patients (18.4%) were asymptomatic. Blood routine tests indicated lymphocytopenia, the proportion of lymphocyte subsets was generally reduced, and chest CT scans showed ground-glass opacity (45.8%) and patchy shadowing (35.4%). However, these findings were not specific to hemodialysis patients with COVID-19, and similar manifestations could be found in patients without SARS-CoV-2 infection. In conclusion, for hemodialysis patients with COVID-19, lymphocytopenia and ground-glass opacities or patchy opacities were common but not specific to them, early active treatment and interventions against nosocomial infection can significantly reduce the mortality and the risk of SARS-CoV-2 infection."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":727,"end":732},"obj":"Phenotype"},{"id":"T2","span":{"begin":745,"end":754},"obj":"Phenotype"},{"id":"T3","span":{"begin":841,"end":856},"obj":"Phenotype"},{"id":"T4","span":{"begin":1225,"end":1240},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0031246"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0001888"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0001888"}],"text":"Clinical features of patients undergoing hemodialysis with COVID-19.\nHemodialysis patients are susceptible to coronavirus disease 2019 (COVID-19). The aim of this study was to describe the epidemiological, clinical characteristics, and mortality-related risk factors for those who undergoing hemodialysis with COVID-19. We conducted a retrospective study. A total of 49 hemodialysis patients with COVID-19 (Group 1) and 74 uninfected patients (Group 2) were included. For patients in Group 1, we found the median age was 62 years (36-89 years), 59.3% were male, and the median dialysis vintage was 26 months. Twenty-eight patients (57%) had three or more comorbidities and two patients (4%) died. The most common symptoms were fever (32.7%) and dry cough (46.9%), while nine patients (18.4%) were asymptomatic. Blood routine tests indicated lymphocytopenia, the proportion of lymphocyte subsets was generally reduced, and chest CT scans showed ground-glass opacity (45.8%) and patchy shadowing (35.4%). However, these findings were not specific to hemodialysis patients with COVID-19, and similar manifestations could be found in patients without SARS-CoV-2 infection. In conclusion, for hemodialysis patients with COVID-19, lymphocytopenia and ground-glass opacities or patchy opacities were common but not specific to them, early active treatment and interventions against nosocomial infection can significantly reduce the mortality and the risk of SARS-CoV-2 infection."}